Boosting nicotinamide adenine dinucleotide (NAD+) improves health in a clinical study
Nicotinamide adenine dinucleotide (NAD+) is an essential metabolic co- factor that is central to energy me- tabolism. During aging, obesity, and diabetes, NAD+ concentrations in cells decline. NAD is synthesized de novo from tryptophan precursors, from nicotinic acid through the Preiss-Handler pathway, or from nicotinamide through the salvage pathway. The rate-limiting enzyme in the sal- vage pathway, nicotinamide phosphoribosyl- transferase (NAMPT), recycles nicotinamide into nicotinamide mononucleotide (NMN), which is converted into NAD+ (see the figure). Restoration of NAD+ concentrations in cells of old or diseased mice through administra- tion of NMN improves health; however, it is unclear whether NMN therapy is practical in humans. On page 1224 of this issue, Yoshino et al. (1) show in a randomized, placebo-con- trolled, double-blind trial that NMN supple- mentation promotes NAD+ metabolism and improves skeletal muscle insulin sensitivity in postmenopausal prediabetic women who are overweight or obese. Thus, NMN may be a viable therapeutic strategy in humans to improve metabolic health during obesity.
To downlod the full paper, please download from:Supplements to treat prediabetes.pdf
Post time: 02-16-2020